WO2010006454A2 - Functionalized polypeptides - Google Patents
Functionalized polypeptides Download PDFInfo
- Publication number
- WO2010006454A2 WO2010006454A2 PCT/CH2009/000225 CH2009000225W WO2010006454A2 WO 2010006454 A2 WO2010006454 A2 WO 2010006454A2 CH 2009000225 W CH2009000225 W CH 2009000225W WO 2010006454 A2 WO2010006454 A2 WO 2010006454A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- linker
- amino acid
- seq
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011103168/10A RU2582244C2 (en) | 2008-06-30 | 2009-06-30 | Functionalised polypeptides |
MX2011000006A MX2011000006A (en) | 2008-06-30 | 2009-06-30 | Functionalized polypeptides. |
AU2009270405A AU2009270405B2 (en) | 2008-06-30 | 2009-06-30 | Functionalized polypeptides |
BRPI0915343A BRPI0915343A2 (en) | 2008-06-30 | 2009-06-30 | functionalized polypeptides |
KR1020117001520A KR101678925B1 (en) | 2008-06-30 | 2009-06-30 | Functionalized polypeptides |
KR1020167010129A KR101711472B1 (en) | 2008-06-30 | 2009-06-30 | Functionalized polypeptides |
JP2011515053A JP5988580B2 (en) | 2008-06-30 | 2009-06-30 | Functional polypeptide |
EP09775731.4A EP2304033B1 (en) | 2008-06-30 | 2009-06-30 | Functionalized polypeptides |
US13/000,499 US8637022B2 (en) | 2008-06-30 | 2009-06-30 | Functionalized polypeptides |
CN2009801247812A CN102089431A (en) | 2008-06-30 | 2009-06-30 | Functionalized polypeptides |
CA2729185A CA2729185A1 (en) | 2008-06-30 | 2009-06-30 | Methods and compositions for modifying immunobinders |
MX2012011299A MX344076B (en) | 2008-06-30 | 2009-06-30 | Functionalized polypeptides. |
ZA2010/08596A ZA201008596B (en) | 2008-06-30 | 2010-11-30 | Functionalized polypeptides |
US14/134,988 US9371525B2 (en) | 2008-06-30 | 2013-12-19 | Functionalized polypeptides |
US15/163,208 US20160354479A1 (en) | 2008-06-30 | 2016-05-24 | Functionalized polypeptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7677508P | 2008-06-30 | 2008-06-30 | |
US61/076,775 | 2008-06-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/000,499 A-371-Of-International US8637022B2 (en) | 2008-06-30 | 2009-06-30 | Functionalized polypeptides |
US14/134,988 Division US9371525B2 (en) | 2008-06-30 | 2013-12-19 | Functionalized polypeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010006454A2 true WO2010006454A2 (en) | 2010-01-21 |
WO2010006454A3 WO2010006454A3 (en) | 2010-03-25 |
Family
ID=41139486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CH2009/000225 WO2010006454A2 (en) | 2008-06-30 | 2009-06-30 | Functionalized polypeptides |
Country Status (12)
Country | Link |
---|---|
US (3) | US8637022B2 (en) |
EP (2) | EP2304033B1 (en) |
JP (3) | JP5988580B2 (en) |
KR (2) | KR101678925B1 (en) |
CN (2) | CN105153300A (en) |
AU (1) | AU2009270405B2 (en) |
BR (1) | BRPI0915343A2 (en) |
CA (1) | CA2729185A1 (en) |
MX (2) | MX344076B (en) |
RU (2) | RU2016108598A (en) |
WO (1) | WO2010006454A2 (en) |
ZA (1) | ZA201008596B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010003268A2 (en) * | 2008-07-10 | 2010-01-14 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
WO2012051734A1 (en) | 2010-10-22 | 2012-04-26 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies |
WO2013056851A2 (en) | 2011-10-20 | 2013-04-25 | Esbatech - A Novartis Company Llc | Stable multiple antigen-binding antibody |
WO2015144852A1 (en) * | 2014-03-26 | 2015-10-01 | Delenex Therapeutics Ag | Binding members to tnf alpha |
WO2021030657A1 (en) * | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Materials and methods for improved single chain variable fragments |
US11098110B2 (en) | 2014-11-07 | 2021-08-24 | Novartis Ag | Methods for treating ocular diseases with brolucizumab |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100056766A1 (en) * | 2008-08-27 | 2010-03-04 | Abbott Laboratories | Purification of biological conjugates by size exclusion chromatography |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001080899A2 (en) * | 2000-04-20 | 2001-11-01 | Cangene Corporation | Rhamm peptide conjugates |
US7211395B2 (en) * | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
US20070202045A1 (en) * | 2002-06-28 | 2007-08-30 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
WO2009000099A2 (en) * | 2007-06-25 | 2008-12-31 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB9225453D0 (en) * | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
US6699658B1 (en) * | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
ATE332368T1 (en) | 1997-01-21 | 2006-07-15 | Gen Hospital Corp | SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS |
WO2000057896A1 (en) | 1999-03-26 | 2000-10-05 | The University Of Texas System | Modulators of polysaccharides and uses thereof |
US20050159343A1 (en) * | 1999-03-26 | 2005-07-21 | Board Of Regents, University Of Texas System | Inhibitors of glycosaminoglycans |
EP1210093A4 (en) | 1999-09-03 | 2005-01-12 | Polytherics Ltd | Degradable polymers |
EP1222217B1 (en) | 1999-09-08 | 2005-06-15 | Polytherics Limited | Uniform molecular weight polymers |
JP2003518075A (en) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | Methods and compositions for extending the elimination half-life of bioactive compounds |
EP2796546B1 (en) | 2001-04-19 | 2017-08-09 | The Scripps Research Institute | Incorporation of unnatural amino acids |
GB0131112D0 (en) | 2001-12-31 | 2002-02-13 | Univ London Pharmacy | Block copolymers |
GB0209022D0 (en) | 2002-04-19 | 2002-05-29 | Imp College Innovations Ltd | Compounds |
HUE048922T2 (en) | 2002-05-22 | 2020-09-28 | Novartis Ag | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
ATE425767T1 (en) | 2002-12-19 | 2009-04-15 | Nektar Therapeutics Al Corp | CONJUGATES OF CYANOVIRIN VARIANTS AND A POLYALKYLENE OXIDE |
US7834258B2 (en) * | 2003-06-30 | 2010-11-16 | Mu-Hyeon Choe | Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
GB0400264D0 (en) | 2004-01-07 | 2004-02-11 | Polytherics Ltd | Complexes |
MX2007000387A (en) * | 2004-07-16 | 2007-03-28 | Micromet Ag | Expression-enhanced polypeptides. |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
EP1797127B1 (en) * | 2004-09-24 | 2017-06-14 | Amgen Inc. | Modified fc molecules |
US20060147862A1 (en) * | 2005-01-06 | 2006-07-06 | Jeffrey Bell | Reduced smoking wick and candle |
US7723472B2 (en) * | 2005-02-28 | 2010-05-25 | The Regents Of The University Of California | Extracellular matrix binding chimeric proteins and methods of use thereof |
NZ563580A (en) | 2005-06-07 | 2010-09-30 | Esbatech An Alcon Biomedical R | Stable and soluble antibodies inhibiting TNFaplha |
EP1929073A4 (en) * | 2005-09-27 | 2010-03-10 | Amunix Inc | Proteinaceous pharmaceuticals and uses thereof |
MX363905B (en) * | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Single-chain multivalent binding proteins with effector function. |
AU2007272224B2 (en) | 2006-07-10 | 2013-05-02 | Novartis Ag | scFv antibodies which pass epithelial and/or endothelial layers |
DK2164961T3 (en) | 2007-06-25 | 2015-03-02 | Esbatech Alcon Biomed Res Unit | Sequence based forward position and optimization of single chain antibodies |
CA3020290A1 (en) * | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting vegf |
-
2009
- 2009-06-30 EP EP09775731.4A patent/EP2304033B1/en not_active Not-in-force
- 2009-06-30 JP JP2011515053A patent/JP5988580B2/en not_active Expired - Fee Related
- 2009-06-30 MX MX2012011299A patent/MX344076B/en unknown
- 2009-06-30 WO PCT/CH2009/000225 patent/WO2010006454A2/en active Application Filing
- 2009-06-30 AU AU2009270405A patent/AU2009270405B2/en not_active Ceased
- 2009-06-30 CN CN201510689528.9A patent/CN105153300A/en active Pending
- 2009-06-30 CA CA2729185A patent/CA2729185A1/en not_active Abandoned
- 2009-06-30 MX MX2011000006A patent/MX2011000006A/en active IP Right Grant
- 2009-06-30 BR BRPI0915343A patent/BRPI0915343A2/en not_active IP Right Cessation
- 2009-06-30 EP EP16187295.7A patent/EP3130603A1/en not_active Withdrawn
- 2009-06-30 KR KR1020117001520A patent/KR101678925B1/en active IP Right Grant
- 2009-06-30 KR KR1020167010129A patent/KR101711472B1/en active IP Right Grant
- 2009-06-30 US US13/000,499 patent/US8637022B2/en not_active Expired - Fee Related
- 2009-06-30 RU RU2016108598A patent/RU2016108598A/en not_active Application Discontinuation
- 2009-06-30 CN CN2009801247812A patent/CN102089431A/en active Pending
- 2009-06-30 RU RU2011103168/10A patent/RU2582244C2/en not_active IP Right Cessation
-
2010
- 2010-11-30 ZA ZA2010/08596A patent/ZA201008596B/en unknown
-
2013
- 2013-12-19 US US14/134,988 patent/US9371525B2/en not_active Expired - Fee Related
-
2014
- 2014-03-19 JP JP2014055758A patent/JP2014111670A/en active Pending
-
2016
- 2016-05-20 JP JP2016101272A patent/JP2016147909A/en active Pending
- 2016-05-24 US US15/163,208 patent/US20160354479A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001080899A2 (en) * | 2000-04-20 | 2001-11-01 | Cangene Corporation | Rhamm peptide conjugates |
US7211395B2 (en) * | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
US20070202045A1 (en) * | 2002-06-28 | 2007-08-30 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
WO2009000099A2 (en) * | 2007-06-25 | 2008-12-31 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
Non-Patent Citations (5)
Title |
---|
CARTER P J: "POTENT ANTIBODY THERAPEUTICS BY DESIGN" NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 6, 7 April 2006 (2006-04-07), pages 343-357, XP007901440 ISSN: 1474-1733 * |
MUMMERT M E ET AL: "DEVELOPMENT OF A PEPTIDE INHIBITOR OF HYALURONAN-MEDIATED LEUKOCYTE TRAFFICKING" JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 192, no. 6, 18 September 2000 (2000-09-18), pages 769-779, XP009081295 ISSN: 0022-1007 cited in the application * |
SHAUNAK SUNIL ET AL: "Site-specific PEGylation of native disulfide bonds in therapeutic proteins" NATURE CHEMICAL BIOLOGY JUN 2006,, vol. 2, no. 6, 1 June 2006 (2006-06-01), pages 312-313, XP002544349 cited in the application * |
VITA CLAUDIO: "Engineering novel proteins by transfer of active sites to natural scaffolds" CURRENT OPINION IN BIOTECHNOLOGY, vol. 8, no. 4, 1997, pages 429-434, XP002551084 ISSN: 0958-1669 * |
ZANETTI M ET AL: "EXPRESSION OF CONFORMATIONALLY CONSTRAINED ADHESION PEPTIDE IN AN ANTIBODY CDR LOOP AND INHIBITION OF NATURAL KILLER CELL CYTOTOXIC ACTIVITY BY AN ANTIBODY ANTIGENIZED WITH THE RGD MOTIF" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 12, no. 11, 1 January 1993 (1993-01-01), pages 4375-4384, XP001194410 ISSN: 0261-4189 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8697074B2 (en) | 2008-07-10 | 2014-04-15 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
WO2010003268A3 (en) * | 2008-07-10 | 2011-01-13 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
WO2010003268A2 (en) * | 2008-07-10 | 2010-01-14 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
EP2769711A1 (en) * | 2008-07-10 | 2014-08-27 | ESBATech, an Alcon Biomedical Research Unit LLC | Methods and Compositions for Enhanced Delivery of Macromolecules |
EP3336105A1 (en) | 2010-10-22 | 2018-06-20 | ESBATech - a Novartis Company LLC | Stable and soluble human tnf alpha antibodies |
US10570198B2 (en) | 2010-10-22 | 2020-02-25 | Novartis Ag | Stable and soluble antibodies |
US8545849B2 (en) | 2010-10-22 | 2013-10-01 | ESBATech, an Aclon Biomedical Research Unit LLC | Stable and soluble antibodies |
US9598487B2 (en) | 2010-10-22 | 2017-03-21 | ESBATech, an Alcon Biomedical Unit LLC | Stable and soluble antibodies |
WO2012051734A1 (en) | 2010-10-22 | 2012-04-26 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies |
EP3431495A1 (en) | 2011-10-20 | 2019-01-23 | ESBATech - a Novartis Company LLC | Stable multiple antigen-binding antibody |
WO2013056851A2 (en) | 2011-10-20 | 2013-04-25 | Esbatech - A Novartis Company Llc | Stable multiple antigen-binding antibody |
RU2706551C2 (en) * | 2014-03-26 | 2019-11-19 | Селл Медика Свитзерлэнд Аг | Binding members to tnf-alpha |
US10233238B2 (en) | 2014-03-26 | 2019-03-19 | Cell Medica Switzerland Ag | TNF alpha antibody or fragment thereof and methods of use |
CN106414498A (en) * | 2014-03-26 | 2017-02-15 | 细胞药物瑞士股份公司 | Binding members to TNF alpha |
WO2015144852A1 (en) * | 2014-03-26 | 2015-10-01 | Delenex Therapeutics Ag | Binding members to tnf alpha |
CN106414498B (en) * | 2014-03-26 | 2020-09-08 | 细胞药物瑞士股份公司 | Binding members for TNF alpha |
US10995138B2 (en) | 2014-03-26 | 2021-05-04 | Cell Medica Inc. | Nucleic acids encoding binding members to TNF alpha |
US11098110B2 (en) | 2014-11-07 | 2021-08-24 | Novartis Ag | Methods for treating ocular diseases with brolucizumab |
WO2021030657A1 (en) * | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Materials and methods for improved single chain variable fragments |
CN114258400A (en) * | 2019-08-15 | 2022-03-29 | 詹森生物科技公司 | Materials and methods for improved single-stranded variable fragments |
US11787875B2 (en) | 2019-08-15 | 2023-10-17 | Janssen Biotech, Inc. | Materials and methods for improved single chain variable fragments |
Also Published As
Publication number | Publication date |
---|---|
BRPI0915343A2 (en) | 2015-10-27 |
KR20160046927A (en) | 2016-04-29 |
JP5988580B2 (en) | 2016-09-07 |
US9371525B2 (en) | 2016-06-21 |
AU2009270405A1 (en) | 2010-01-21 |
EP3130603A1 (en) | 2017-02-15 |
RU2582244C2 (en) | 2016-04-20 |
ZA201008596B (en) | 2012-02-29 |
JP2014111670A (en) | 2014-06-19 |
MX344076B (en) | 2016-12-05 |
JP2016147909A (en) | 2016-08-18 |
RU2011103168A (en) | 2012-08-10 |
MX2011000006A (en) | 2011-08-03 |
US20110200594A1 (en) | 2011-08-18 |
JP2011526145A (en) | 2011-10-06 |
RU2016108598A (en) | 2018-11-23 |
CA2729185A1 (en) | 2010-01-21 |
US20140178386A1 (en) | 2014-06-26 |
KR101711472B1 (en) | 2017-03-02 |
AU2009270405B2 (en) | 2014-06-05 |
EP2304033A2 (en) | 2011-04-06 |
KR20110039274A (en) | 2011-04-15 |
KR101678925B1 (en) | 2016-11-24 |
US20160354479A1 (en) | 2016-12-08 |
WO2010006454A3 (en) | 2010-03-25 |
US8637022B2 (en) | 2014-01-28 |
CN102089431A (en) | 2011-06-08 |
CN105153300A (en) | 2015-12-16 |
EP2304033B1 (en) | 2016-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9371525B2 (en) | Functionalized polypeptides | |
US9775912B2 (en) | Designed repeat proteins binding to serum albumin | |
US9314537B2 (en) | SPARC binding ScFcs | |
KR101151805B1 (en) | Bipodal Peptide Binder | |
US20240100129A1 (en) | Serum Albumin-Binding Fibronectin Type III Domains | |
US9867886B2 (en) | Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof | |
EP1955712A1 (en) | Multimeric conjugate | |
EP3119803B1 (en) | Stabilized fibronectin based scaffold molecules | |
KR20120125455A (en) | Intracelluar targeting bipodal peptide binder | |
AU2014215955B2 (en) | Functionalized polypeptides | |
AU2016253633A1 (en) | Functionalized polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980124781.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09775731 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009270405 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2011515053 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13000499 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4906/KOLNP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2729185 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/000006 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2009270405 Country of ref document: AU Date of ref document: 20090630 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2009775731 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009775731 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117001520 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011103168 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0915343 Country of ref document: BR Kind code of ref document: A2 Effective date: 20101229 |